SecBot SecBot
8-K ·Filed May 13, 2026

ABEO

ABEONA THERAPEUTICS INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001493152-26-022610
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

ZEVASKYN commercial ramp is progressing with 3 patients treated in Q1 and 6+ biopsies expected in Q2, but the company remains pre-profitability with widening losses. The $168.3M cash runway provides ~2 years of funding at current burn rates. The ABO-701 licensing adds pipeline optionality but is early-stage (IND filing H2 2027). Monitor Q2 patient treatment cadence and any guidance on revenue trajectory.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Abeona Therapeutics reported Q1 2026 net product revenue of $8.7M, up from $2.4M in Q4 2025, driven by three ZEVASKYN patient treatments. Net loss widened to -$17.1M (-$0.30/share) from -$12.0M (-$0.24/share) in Q1 2025, reflecting increased SG&A costs from commercial scaling and a $7.0M upfront licensing payment for the new ABO-701 T-cell therapy program. Cash and investments totaled $168.3M, down from $191.4M at year-end 2025.

Key Financial Metrics

EPS
−$0.30
est −$0.33 · +9.1%
Revenue
$8.7M
est $4.9M · +78.0%
Rating
in line

Key Facts

  • Q1 2026 net product revenue of $8.7M vs $2.4M in Q4 2025 (quarter-over-quarter increase of $6.3M)
  • Three ZEVASKYN patient treatments completed in Q1 2026; one additional in early Q2
  • QTC network expanded to six sites with activation of NY-Presbyterian/Columbia and CHOP
  • Net loss of -$17.1M (-$0.30/share) vs -$12.0M (-$0.24/share) in Q1 2025
  • Cash, cash equivalents and short-term investments of $168.3M as of March 31, 2026
  • In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; $7.0M upfront payment
  • Ophthalmology programs deprioritized as part of portfolio optimization
  • Published coverage policies in place for 95% of commercially insured U.S. lives

Financial Impact

Q1 2026 net product revenue $8.7M; net loss -$17.1M; cash burn ~$23.1M in Q1

revenuenet losscash position

Risk Factors

  • Commercial execution risk, ZEVASKYN revenue still nascent with only 3 patients treated in Q1
  • Widening net loss and operating expenses as commercial infrastructure scales
  • ABO-701 is pre-clinical; IND filing not expected until H2 2027 with no near-term value
  • Cash burn of ~$23M/quarter; runway of ~7 quarters at current pace

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-022610
Document: form8-k.htm0001493152-26-022610
Document: 0001493152-26-022610-index-headers.html0001493152-26-022610
Document: 0001493152-26-022610-index.html0001493152-26-022610
Document: 0001493152-26-022610.txt0001493152-26-022610
8-K Data (Synthetic)0001493152-26-022610

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026